Impact of Myo-Inositol-Chiro Inositol Combination on the improvement of Polycystic Ovary Syndrome Condition

Abstract Background: Inositol was previously classified as a vitamin, but it is not one as it is produced by the body. It plays a role as a second messenger of insulin in several insulin-dependent processes, including polycystic ovarian syndrome (PCOS) and metabolic syndrome. Objective: This study aims to determine the impact of myo+ D-chiro inositol treatment on gut hormones insulin-like peptide 5 (ILP5) and phosphodiesterase 9 (PDE9) inhibitors, as well as determine if it improves the metabolic profile and the state of PCOS. Materials and Methods: The research conducted by the University of Baghdad’s College of Medicine was authorized by the ethics committee. In the study, 50 obese women without PCOS, and 50 obese women with PCOS were enrolled, and they were then treated with 2000 mg of myo-inositol (MI) and 50 mg of D-chiro inositol (DCI) in a 40:1 ratio for 3 months while having their vital signs and laboratory tests checked both before and after the treatment. We examined fasting glucose, insulin, ILP5, PDE9 inhibitor, free testosterone, dehydroepiandrosterone, the homeostatic model assessment index, and pretreatment and posttreatment. From February 2022 to the end of August 2022, participants in the study visited the Infertility Unit at the Higher Institute for Infertility Diagnosis and Assisted Reproductive Technologies at Al-Nahrain University in Baghdad, Baghdad, Iraq. Participants in this research completed questionnaires to indicate their consent for the study to record information on women. Results: The results revealed that after administering the treatment to polycystic ovary patients, a significant decrease in their weight and an improvement in insulin resistance markers were observed, as well as a decrease in the levels of ILP5 (171.53 ± 22.55 vs. 83.60 ± 18.94), and an increase in the levels of phosphodiesterase9 enzyme (7.17 ± 1.58 ng/mL vs. 8.16 ± 1.37 ng/mL). Conclusion: This study concludes that MI–DCI could be proposed as a potential therapeutic approach for the treatment of women with polycystic ovaries, showing a positive effect on correcting PCOS symptoms and infertility.